Myelofibrosis Care: Pharmacist Role and Treatment Challenges

Now Viewing

EP: 1.Myelofibrosis Care: Pharmacist Role and Treatment Challenges

EP: 2.Blood Shortages Impacting Myelofibrosis Care

EP: 3.Challenges in Myelofibrosis: Red Blood Cell Transfusion Shortages

EP: 4.Impact and Adoption of Momelotinib in Myelofibrosis

EP: 5.Emerging Therapies and Momelotinib Impact

EP: 6.Inpatient to Outpatient: Myelofibrosis Care

EP: 7.Challenges in Outpatient Transition For Myelofibrosis Care

EP: 8.Navigating Myelofibrosis Transitions

EP: 9.Pharmacist-Led Patient Education Strategies

EP: 10.Addressing Socioeconomic Barriers in Myelofibrosis Care

EP: 11.Patient Advocacy in Myelofibrosis Care

EP: 12.Tailoring Myelofibrosis Care: Patient Preferences and Challenges

EP: 13.Advancements in Myelofibrosis Care: Pharmacists' Perspectives

This is a video synopsis/summary of a Peer Exchange involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; Shawn Griffin, PharmD, BCOP; and Robert Mancini, PharmD, BCOP, FHOPA.

In a Pharmacy Times® Peer Exchange led by Mahmoudjafari, a panel, including Davis and Nachar, discuss the pharmacist’s role in myelofibrosis care. Davis outlines challenges faced by patients with myelofibrosis, emphasizing symptoms and the impact on survival. The conversation focuses on the treatment landscape, highlighting Janus kinase inhibitors’ role and associated anemia challenges, leading to treatment discontinuation in over 30% of cases. Nachar adds insights into multifactorial anemia causes and treatment options, including androgens, immunomodulatory agents, and the recently approved momelotinib. The historical use of blood cell transfusions is also mentioned. This concise exchange underscores pharmacists’ crucial role in addressing myelofibrosis challenges and the evolving treatment strategies.

This summary was AI-generated and reviewed by Pharmacy Times^® editorial staff.